IE
KYTX icon

Israel Englander’s Kyverna Therapeutics KYTX Stock Holding History

Israel Englander’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.7M Sell
639,780
-365,728
-36% -$3.25M ﹤0.01% 2861
2026
Q1 		$8.68M Buy
1,005,508
+412,139
+69% +$3.43M ﹤0.01% 2308
2025
Q4 		$5.58M Buy
593,369
+41,734
+8% +$310K ﹤0.01% 2889
2025
Q3 		$3.31M Buy
551,635
+99,075
+22% +$396K ﹤0.01% 3550
2025
Q2 		$1.39M Buy
452,560
+214,321
+90% +$530K ﹤0.01% 4182
2025
Q1 		$460K Sell
238,239
-508,282
-68% -$1.5M ﹤0.01% 4867
2024
Q4 		$2.79M Sell
746,521
-507,035
-40% -$2.43M ﹤0.01% 3371
2024
Q3 		$6.13M Buy
1,253,556
+330,474
+36% +$2.55M ﹤0.01% 2664
2024
Q2 		$6.92M Buy
923,082
+227,988
+33% +$3.48M ﹤0.01% 2404
2024
Q1 		$17.3M Buy
+695,094
New +$19.4M 0.01% 1682

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Israel Englander's KYTX Position: Q2 2026 in Review

Israel Englander reduced its Kyverna Therapeutics (KYTX) stake by 36% in Q2 2026, selling an estimated $3.25M and leaving 639,780 shares worth $5.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2861.

Israel Englander first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $17.3M in Q1 2024. 119 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Israel Englander held 639,780 shares of Kyverna Therapeutics worth $5.7M as of Q2 2026.
  • Israel Englander sold 365,728 Kyverna Therapeutics shares in Q2 2026, an estimated $3.25M.
  • Kyverna Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2861 holding.
  • Israel Englander first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Israel Englander's Kyverna Therapeutics position peaked at $17.3M in Q1 2024.
  • 119 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.